All In Biotech

Free tool

FAERS Monitor: Ravicti

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203284 or its brand name (Ravicti, Glycerol Phenylbutyrate). Reports on generic versions are filed under their own applications.

Reports

1,392

Serious

843

61% of reports

Hospitalization

624

Death reported

66

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • ammonia increased207
  • vomiting168
  • hyperammonaemia166
  • decreased appetite106
  • nausea74
  • headache66
  • hyperammonaemic crisis64
  • off label use63
  • diarrhoea58
  • fatigue53
  • somnolence53
  • weight decreased47
  • malaise46
  • seizure44
  • lethargy40

Reports by year received

View as table
YearReports
20139
201420
2015270
2016260
2017102
201881
201996
202063
202129
202233
2023106
2024193
202543
202687

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,767 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hyperammonaemic crisisSignal6422510.315349.5569,897
ammonia increasedSignal207638.9561.7125,917
hyperammonaemiaSignal166518.7448.582,451
lethargySignal4010.57.7336
decreased appetiteSignal1066.95.7534
seizureSignal445.84.3169
vomitingSignal1685.44.7611
somnolenceSignal534.03.1116
weight decreasedSignal472.51.943
headache661.61.314
malaise461.61.210
nausea741.41.19
diarrhoea581.41.15
off label use631.10.90
fatigue531.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.